Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

ABSTRACT:

Background

Myxoid liposarcoma is a histological subtype of liposarcoma particularly sensitive to trabectedin. In clinical use this drug does not cause cumulative toxicity, allowing prolonged treatment, generally until disease progression. No other effective therapies are available for trabectedin-resistant patients.

Methods

Through repeated in vivo treatment in athymic nude mice, we have obtained a patient-derived xenograft with acquired resistance to trabectedin.

Results

At basal level, the morphology of the resistant and sensitive models did not differ, in keeping with the finding that the transcriptional profiles of the resistant and sensitive tumours were very similar. After trabectedin treatment adipogenesis was induced in the parental xenograft but not in the re

SUBMITTER: Bello E 

PROVIDER: S-EPMC6738121 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature